Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease

Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease

ABSTRACTPrimary effusion lymphoma (PEL), an aggressive non-Hodgkin lymphoma caused by Kaposi sarcoma-associated herpesvirus (KSHV), lacks standard therapy and has a median survival of 10–22 months with combination chemotherapy. PEL is a tumor of plasmablast-like B cells generally expressing CD38, th...

Full description

Bibliographic Details
Main Authors: Prabha Shrestha, Yana Astter, David A. Davis, Ting Zhou, Constance M. Yuan, Ramya Ramaswami, Hao-Wei Wang, Kathryn Lurain, Robert Yarchoan
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:OncoImmunology
Subjects:
Daratumumab
primary effusion lymphoma (PEL)
pomalidomide
rituximab
all-trans retinoic acid (ATRA)
CD38
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2022.2163784

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2022.2163784

Similar Items